Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
893 S Delaware St
Indianapolis, IN 46285
  • Featured Employer
Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.
We are Lilly
Why do our employees love coming to work each and every day? Here’s what they have to say.
  • “Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”
    Kavita - Associate Director, Packaging Operations
  • “Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”
    Adrian - Associate Director, IDM
  • “What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”
    Cecile - Sr Director, Design Hub Foundations
39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.
NEWS
Shares of Eli Lilly jumped in premarket trading after the company reported total revenue of $6.35 billion for the second quarter, a 9 percent increase in revenue over the same period last year.
Anima Biotech, based in Bernardsville, New Jersey, inked a discovery and development deal with Eli Lilly and Co. that has the potential to exceed $1 billion.
Pfizer and Eli Lilly released results from its 16-week Phase III clinical trial in patients with osteoarthritis (OA) pain receiving a subcutaneous dose of tanezumab. The drug hit all three co-primary endpoints.
Gilead may be down, but at least one analyst thinks the company is poised for a turnaround.
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
This week had a few disappointing clinical trials, as do most weeks, but it also had a number of significant successes. Here’s a look at some of the clinical trials that met their primary endpoints this week.
Eli Lilly and Company announced the results of its COAST-W Phase III clinical trial of Taltz (ixekizumab) to treat Ankylosing Spondylitis (AS). The trial met both primary and major secondary endpoints.
The Dementia Discovery Fund (DDF), a venture capital fund focused solely on dementia-related investments, completed $350 million of fundraising. The initial target was $200 million.
Akero Therapeutics, headquartered in Cambridge, Massachusetts, closed on a $65 million Series A financing round.
JOBS
IN THE PRESS